Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis  

作　　者：Yasushi Umehara Masatoshi Kudo Masanori Kawasaki 

机构地区：[1]Division of Gastroenterology and Hepatology,Department of Internal Medicine Kinki University School of Medicine

出　　处：《World Journal of Gastroenterology》2008年第34期5316-5321,共6页世界胃肠病学杂志（英文版）

摘　　要：AIM:To investigate the therapeutic usefulness of leukocytapheresis (LCAP; Cellsoba) in steroid-naive patients with moderately active ulcerative colitis (UC). METHODS: Eighteen steroid-naive patients with moderately active UC received one LCAP session every week for fi ve consecutive weeks. RESULTS: The remission rate 8 weeks after the last LCAP session was 61.1% (11/18). All three patients with deep ulcers showed worsening after LCAP. For the remaining 15 patients, who had erosions or geographic ulcers, the average clinical activity index (CAI) score dropped significantly from 9.4 to 3.8 eight weeks after the last LCAP session (t = 4.89, P = 0.001). The average C-reactive protein (CRP) levels before and after LCAP were 1.2 mg/dL and 1.0 mg/dL, respectively. Of the patients with erosions, geographic ulcers, and deep ulcers, 100% (9/9), 33.3% (2/6), and 0% (0/3) were in remission 8 weeks after the last LCAP session, respectively (χ2 = 7.65, P < 0.005). Forty- eight weeks after the last LCAP session, the remission rates for patients with erosions and geographic ulcers were 44.4% (4/9) and 16.7% (1/6), respectively. Only one patient suffered a mild adverse event after LCAP (nausea). CONCLUSION: LCAP is a useful and safe therapyfor steroid-naive UC patients with moderate disease activity. Moreover, the effi cacy of the treatment can be predicted on the basis of endoscopic fi ndings.AIM：To investigate the therapeutic usefulness of leukocytapheresis （LCAP; Cellsoba） in steroid-naive patients with moderately active ulcerative colitis （UC）. METHODS： Eighteen steroid-naive patients with moderately active UC received one LCAP session every week for fi ve consecutive weeks. RESULTS： The remission rate 8 weeks after the last LCAP session was 61.1% （11/18）. All three patients with deep ulcers showed worsening after LCAP. For the remaining 15 patients, who had erosions or geographic ulcers, the average clinical activity index （CAI） score dropped significantly from 9.4 to 3.8 eight weeks after the last LCAP session （t = 4.89, P = 0.001）. The average C-reactive protein （CRP） levels before and after LCAP were 1.2 mg/dL and 1.0 mg/dL, respectively. Of the patients with erosions, geographic ulcers, and deep ulcers, 100% （9/9）, 33.3% （2/6）, and 0% （0/3） were in remission 8 weeks after the last LCAP session, respectively （χ2 = 7.65, P 〈 0.005）. Forty- eight weeks after the last LCAP session, the remission rates for patients with erosions and geographic ulcers were 44.4% （4/9） and 16.7% （1/6）, respectively. Only one patient suffered a mild adverse event after LCAP （nausea）. CONCLUSION： LCAP is a useful and safe therapyfor steroid-naive UC patients with moderate disease activity. Moreover, the effi cacy of the treatment can be predicted on the basis of endoscopic fi ndings.

关 键 词：Ulcerative colitis Steroid-naive LEUKOCYTAPHERESIS EFFICACY Endoscopic findings 

分 类 号：R574.62[医药卫生—消化系统] R445[医药卫生—内科学]